A comparison of a new multinomial stopping rule with stopping rules of...
AbstractBackgroundResponse rate (RR) alone may be insensitive to drug activity in phase II trials. Early progressive disease (EPD) could improve sensitivity as well as increase stage I stopping rates....
View ArticleChromosome 17 centromere (CEP17) duplication as a predictor of anthracycline...
AbstractHER2 gene amplification and topoisomerase IIα gene (TOP2A) alteration have been associated with increased benefit from anthracycline compared to non-anthracycline containing adjuvant breast...
View ArticleTIMP-1 in combination with HER2 and TOP2A for prediction of benefit from...
AbstractHER2 amplification, TOP2A aberrations, and absence of tissue inhibitor of metalloproteinase (TIMP-1) expression in breast carcinomas have been shown to be associated with incremental benefit...
View ArticleJackknifed random weighting for Cox proportional hazards model
AbstractThe Cox proportional hazards model is the most used statistical model in the analysis of survival time data. Recently, a random weighting method was proposed to approximate the distribution of...
View ArticleDifferential Role of Estrogen Receptor Beta in Early Versus Metastatic...
AbstractAlthough women have an increased susceptibility to lung cancer, they also have a favorable clinical outcome. This may in part be due to female specific genetic and hormonal factors. In the...
View ArticleLipid concentrations in postmenopausal women on letrozole after 5 years of...
AbstractTo evaluate changes in serum lipid parameters (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and lipoprotein(a) [Lp(a)]), in postmenopausal women receiving letrozole after...
View ArticleUpdate on the Colon Health and Life-Long Exercise Change Trial: A Phase III...
AbstractThe Colon Health and Life-Long Exercise Change (CHALLENGE) trial is evaluating the effects of a 3-year exercise program on disease-free survival in 962 patients with resected high-risk stage II...
View ArticleJointly modeling longitudinal proportional data and survival times with an...
AbstractMotivated by the joint analysis of longitudinal quality of life data and recurrence free survival times from a cancer clinical trial, we present in this paper two approaches to jointly model...
View ArticleRandomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel...
AbstractBackgroundA recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2) in...
View ArticleCanadian Cancer Trials Group IND197: a phase II study of foretinib in...
Abstract In murine models, overexpression of the MET receptor transgene induces tumors with human basal gene expression characteristics supporting MET inhibition as a treatment strategy for...
View ArticleJoint modeling of longitudinal proportional measurements and survival time...
AbstractIn cancer clinical trials and other medical studies, both longitudinal measurements and data on a time to an event (survival time) are often collected from the same patients. Joint analyses of...
View ArticleRecent Development in the Joint Modeling of Longitudinal Quality of Life...
AbstractIn cancer clinical trials, longitudinal Quality of Life (QoL) measurements and survival time on a patient may be analyzed by joint models, which provide more efficient estimation than modeling...
View ArticleAdvantages of the net benefit regression framework for trial-based economic...
AbstractBackgroundEconomic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of...
View ArticleA phase Ib study of a PI3Kinase inhibitor BKM120 in combination with...
SummaryBackground Resistance to Epidermal Growth Factor inhibition (EGFRi) in patients with KRAS wild-type (wt) Colorectal Cancer (CRC) may occur as a result of PI3K/AKT/mTOR signaling. We conducted a...
View ArticleA phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with...
SummaryThe PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in resistance to anti-cancer therapies. Inhibition of the PI3K pathway...
View ArticleVariation in the UGT2B17 genotype, exemestane metabolism and...
AbstractPurposeTo examine associations between the UGT2B17 gene deletion and exemestane metabolites, and commonly reported side effects (fatigue, hot flashes, and joint pain) among postmenopausal women...
View ArticleFactors predicting missing instruments in three cancer randomized clinical...
AbstractPurposeMissing patient-reported outcome (PRO) data can seriously threaten the validity of randomized clinical trials (RCTs). Identifying which factors predict missing instruments may help...
View ArticlePredicting the clinical outcomes and benefit from letrozole after 5 years of...
AbstractPurposeWomen with hormone receptor positive breast cancer may receive 5 years of treatment with aromatase inhibitors but the magnitude of benefit was relatively small. Our goal was to develop a...
View ArticleA robust threshold t linear mixed model for subgroup identification using...
AbstractSubgroup identification has emerged as a popular statistical tool to access the heterogeneity in treatment effects based on specific characteristics of patients. Recently, a threshold linear...
View ArticleA Selective Overview of Statistical Methods for Identification of the...
AbstractIdentification of a subset of patients who may benefit from or be sensitive to a specific type of treatment has become a very important research topic in clinical trials and other types of...
View Article
